EGFR-TKI 的迭代使 EGFR 突变非小细胞肺癌（NSCLC）患者的生存预后得到了极大的改善，但耐药问题仍不可避免。MET 扩增常继发于其他驱动基因阳性 NSCLC 患者靶向治疗后，是 EGFR-TKI 耐药的主要机制之一，因此掌握 ...

Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by in situ hybridization. Mechanisms of EGFR upregulation are dependent on the ...

Activation of EGFR by epidermal growth factor (EGF ... immunofluorescence and immunohistochemistry, use antibodies against specific histone PTMs to understand the state of the histone and its ...

with a widely used immunohistochemistry kit. The therapeutic dependence of EGFR modulation on the degree of receptor expression continues to be controversial; Pirker et al. 1 provide no details as ...

[2] Good evidence exists for the use of anti-EGF receptor (EGFR) monoclonal antibody treatment as part of first-line combination chemotherapy including infusional 5-fluorouracil and for third-line ...